537 related articles for article (PubMed ID: 28397696)
1. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
2. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
[TBL] [Abstract][Full Text] [Related]
3. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
Polaris Observatory HCV Collaborators
Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
[TBL] [Abstract][Full Text] [Related]
4. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
5. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
7. Securing sustainable funding for viral hepatitis elimination plans.
Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
[TBL] [Abstract][Full Text] [Related]
8. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
9. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study.
Dugan E; Blach S; Biondi M; Cai Z; DePaola M; Estes C; Feld J; Gamkrelidze I; Kottilil S; Ma S; Mathur P; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Schmelzer J; Razavi H
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):169-184. PubMed ID: 33515496
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
[TBL] [Abstract][Full Text] [Related]
11. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
12. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
[TBL] [Abstract][Full Text] [Related]
14. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
15. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
Polaris Observatory HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):161-176. PubMed ID: 28404132
[TBL] [Abstract][Full Text] [Related]
16. Global timing of hepatitis C virus elimination in high-income countries.
Razavi H; Sanchez Gonzalez Y; Yuen C; Cornberg M
Liver Int; 2020 Mar; 40(3):522-529. PubMed ID: 31815353
[TBL] [Abstract][Full Text] [Related]
17. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
[TBL] [Abstract][Full Text] [Related]
18. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
[TBL] [Abstract][Full Text] [Related]
19. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
20. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
Dore GJ; Hajarizadeh B
Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
